| Popis: |
Backgrounds: AXIS trial showed the effectiveness of axitinib in 2nd-line with advanced renal cell carcinoma (RCC) patients and significantly higher response rate than sorafenib.(PR + SD;19.6% vs9.2%, p value Material and Methods: Twenty-four cases received axitinib in Nagoya Universuty between September 2010 and December 2013. Results: Two cases was preoperative cases, 1st-line was 3cases, 2nd was 7cases, 3rd was 6cases, 4th was 5cases and 5th-line was one case. The median was 68 year-old (35-83 years), and the median the period of using axtinib was 112 days (4-1157 days). Eight cases were valid for one year or more, 9 cases were progression in less than three months. Nine cases has been already cancer death, 15 cases were received some treatments. In adverse events by CTCAE ver4.0, the hypertension had grade1; 3cases, grade2; 8 cases, and grade3; 3 cases and the proteinuria were found seven cases of the Grade3. Six cases had hoarseness and 3 cases were found with epistaxis. Summary: We evaluated the outcome of axitinib for advanced RCC in Nagoya University. |
